Lv2
119 积分 2025-10-28 加入
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
29天前
已完结
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
1个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
1个月前
已完结
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
2个月前
已完结
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
2个月前
已完结
Efficacy of HS-10382 (TERN-701) in tumor xenograft models, a new investigational allosteric ABL1 kinase inhibitor as a potential treatment for CML
3个月前
已关闭
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
3个月前
已完结
The story of amylin: from physiology to therapy
3个月前
已完结
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
4个月前
已完结
KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress
4个月前
已完结
皖公网安备34019202002308
